Transgene

Beleggen in aandelen beurzen Frankfurt DAX, Londen FTSE 100, Parijs CAC40
gigagoeroe
Forum actieveling
Forum actieveling
Berichten: 839
Lid geworden op: 11 okt 2012 20:17
waarderingen: 356
Contacteer:

Re: Transgene

Bericht door gigagoeroe »

And its gone! schreef:Er is wat aan de hand met onze Transgene merk ik op.

- First efficacy results of the combination trial of TG4001 to be presented at ESMO
on September 30, 2019
Dit zou wel eens goed nieuws kunnen zijn. Koers sluipt vandaag richting +5%.
Partners Pfizer & Merck ;)

Kleine aankoop aan 1.89€ gedaan. gemidd 2.68€.
Ik steun.
Ook kleine aankoop aan 1.94. gemidd 1.94 ;)
And its gone! liked last!



Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 631
Lid geworden op: 30 mei 2018 21:25
waarderingen: 242
Contacteer:

Re: Transgene

Bericht door And its gone! »

En daar is de 2€ terug! :clap:
goed volume.

TRANSGENE (TNG)
ISIN: FR0005175080

LAATSTE
(24/09/19 - 15:02)
2,015
WIJZIGING
(0,075)
3,87%
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 631
Lid geworden op: 30 mei 2018 21:25
waarderingen: 242
Contacteer:

Re: Transgene

Bericht door And its gone! »

Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
BOURSORAMA•30/09/2019 à 17:45
- Three of six patients showed durable responses (patients treated with the recommended Phase 2 dose)1
- Combination therapy results in changes in tumor microenvironment shifting immune status from "cold" to "hot"
- Clinical trial conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer


Conference call scheduled on October 3, 2019 at 2:30 p.m. CET

Strasbourg, France, September 30, 2019, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today presented promising safety and efficacy data of TG4001 in combination with avelumab (BAVENCIO®), a human anti-programmed death ligand (PD-L1) antibody, in HPV-16+ recurrent or metastatic malignancies (including oropharyngeal cancers). These Phase 1b data have been presented in a poster (#1210P) at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain. TG4001 is a therapeutic vaccine based on a Vaccinia vector (MVA), which is engineered to express HPV-16 antigens (E6 & E7). It has been administered to more than 300 individuals in previous trials, demonstrating good safety, significant HPV clearance rate and promising efficacy results.

.../...
Transgene Reports First Promising Efficacy ResultswithTG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019✓Three of sixpatientsshowed durable responses(patients treated with the recommended Phase 2 dose)1✓Combination therapy results inchanges in tumor microenvironment shifting immune status from “cold” to “hot” ✓Clinical trial conducted in collaboration with Merck KGaA, Darmstadt, Germany, and PfizerConference call scheduled on October 3, 2019 at 2:30p.m. CET Strasbourg, France, September 30, 2019, 5:45p.m.


CET –Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeuticsagainst cancer, today presentedpromisingsafety and efficacy data ofTG4001 in combination withavelumab(BAVENCIO®), a human anti-programmed death ligand (PD-L1) antibody, inHPV-16+ recurrent or metastatic malignancies(including oropharyngeal cancers).ThesePhase 1bdata have beenpresented in a poster(#1210P)at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain. TG4001 is a therapeutic vaccine based on a Vacciniavector (MVA), which is engineered to express HPV-16 antigens (E6 & E7).It has been administered to more than 300 individualsin previous trials, demonstrating good safety, significant HPV clearance rate and promising efficacy results.In the Phase 1b part of the trial, 9heavily pretreatedpatients received either one of the two tested doses of TG4001 combined with a fixed dose of avelumab. The Phase 2 part of the trial started inOctober2018and will enroll 40 patients.Key results of the Phase 1b trialare:•3of the 6 patientstreated with the higher dose of TG4001showeddurable partial responses1.•No dose-limiting toxicitywas observed, confirming a good safety profile ofthe combined regimen.•T cellresponsesagainst the HPV-16 E6 and E7 antigenswere detected in patients’ blood at day 43.•The combination regimen was able to prime the immune systemand modified positively the tumors microenvironment. Patients displayed increased immune cells infiltrates(including CD8 T cells) and an increased expression of genes associated with innate and adaptive immune response. •An increase in PD-L1 expressionin the tumor cellswas seen.Dr. Maud Brandely, MD, PhD, Chief Medical Officer of Transgene,commented, “These Phase 1b results with a combination treatment regimen containing TG4001are promising. In this heavily pretreated population, the quality of the responses, in particular the duration of the responses,and the immune changes in the tumor, give us great confidence that we will see a positive outcome from the ongoing Phase2 part of the trial. The results also confirm our conviction that a HPV-16 targeted therapeutic vaccine would be able to stimulate the immune response, and can advantageously be combined withanimmune 1These data compare favorably with current treatments in HPV-16associated indicationsfor patients with metastatic diseases receiving a second line of treatment. Withimmune checkpoint inhibitors, median overall survival remains inferiorto 11months and median progression free survival is between2 and 4 months. In this heterogenous group of malignancies,overall response rates are around 10-15%.
Page 2/4checkpoint inhibitor. Based on these results, I believe that thecombination ofTG4001and an ICIcould potentially offer a much-improved treatment optionthan single agent immune checkpoint inhibitorfor patients with HPV-16+ recurrent or metastatic malignancies.Patient accrual in the Phase 2 part of the trial is in line with our expectations and the next clinical readout is expected in 1H 2020.”Poster presentation -September 30, 2019, 12:00-13:00 -Poster Area Hall 4Title: Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers(ID 2536) Poster #1210P | Presenter: Christophe Le Tourneau (Institut Curie, Paris, France)The abstract is available on the ESMO website. The poster isavailableon Transgene’s website(Publication section)www.transgene.fr. About the trial This multi-center, open-label trial is assessing the safety and tolerability, as well as the anti-tumor activity of this immunotherapy combination regimen (TG4001 + avelumab) in approximately50 patients with HPV-16 positive cancers who had failed at leastone line of systemic treatmentfor R/M disease (NCT03260023). Prof. Christophe Le Tourneau, M.D., PhD, Head of the Department of Drug Development and Innovation (D3i) at the Curie Institute, and a world expert in head and neck cancers, is the Principal Investigator of the study. The trial is conducted in collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company which in the US and Canada operates its biopharmaceutical business as EMD Serono, and Pfizer Inc (NYSE: PFE).In the Phase 1 part, 9 patients were enrolled to either one of the two doses of the vaccine (5x106and 5x107pfu). TG4001 was administered SC weekly for 6 weeks, every 2 weeks up to M6, and every 12 weeks thereafter. Avelumab was given IV at 10mg/kg every 2 weeks. Tumor response was assessed by RECIST1.1. For translational and immunological assessments, PBMC samples were collected longitudinally and tissue samples were collected at baseline and D43.The Phase 2 part of the trialstarted in October2018. 40 patients will be enrolled. Theywill receive the highest TG4001 dose tested in the Phase 1b part of the trial (5x107pfu), in combination with avelumab at 10 mg/kg.The primary endpoint of the Phase 2 part is overall response rate. Secondary endpoints include progression free survival, overall survival, disease control rate and other immunological parameters. The interim readout is expected in 1H 2020
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 631
Lid geworden op: 30 mei 2018 21:25
waarderingen: 242
Contacteer:

Re: Transgene

Bericht door And its gone! »

TRANSGENE presenteert eerste veelbelovende gegevens over de werkzaamheid bij HPV-positieve kankers
AOF • 30/09/2019 om 18:01
(AOF) - Transgene heeft veelbelovende veiligheids- en werkzaamheidsresultaten gepresenteerd voor TG4001 in combinatie met avelumab (BAVENCIO), een gehumaniseerd monoklonaal antilichaam tegen PD-L1, bij recidiverende of gemetastaseerde HPV-16 + 2-kankers, zoals orofaryngeale carcinomen. Deze resultaten van fase 1b werden gepresenteerd in een poster tijdens de jaarlijkse conferentie van de European Society of Medical Oncology in Barcelona. TG4001 is een therapeutisch vaccin dat is ontwikkeld op basis van een Vaccinia-virus (MVA) dat HPV-16 E6- en E7-antigenen tot expressie brengt.

Het is al aan meer dan 300 personen toegediend en heeft goede veiligheid, significante HPV-eliminatie en veelbelovende werkzaamheidsresultaten aangetoond.
Gillepils liked last!
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 631
Lid geworden op: 30 mei 2018 21:25
waarderingen: 242
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Transgene Reports Promising Efficacy Results With TG4001 In Combination With Avelumab
18:16 (30/09) - Bron: Reuters
Sept 30 (Reuters) - Transgene SA TRNG.PA :
* TRANSGENE REPORTS FIRST PROMISING EFFICACY RESULTS WITH TG4001 IN COMBINATION WITH
AVELUMAB IN
HPV-POSITIVE CANCER AT ESMO 2019
* THREE OF SIX PATIENTS SHOWED DURABLE RESPONSES (PATIENTS TREATED WITH RECOMMENDED PHASE 2
DOSE)
* COMBINATION THERAPY RESULTS IN CHANGES IN TUMOR MICROENVIRONMENT SHIFTING IMMUNE STATUS
FROM
"COLD" TO "HOT"
* CLINICAL TRIAL CONDUCTED IN COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
:clap: :clap: :clap:
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 631
Lid geworden op: 30 mei 2018 21:25
waarderingen: 242
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Transgene Q3 Operating Income Down At 3.8 Million Euros
18:18 (14/11) - Bron: Reuters
Nov 14 (Reuters) - TRANSGENE SA TRNG.PA :
* TRANSGENE PROVIDES Q3 2019 BUSINESS UPDATE, WITH FOCUS ON
RECENTLY ANNOUNCED EFFICACY RESULTS OF TG4001
* EUR 54 MILLION IN CASH AND CASH EQUIVALENTS AS OF
SEPTEMBER 30,
2019
* Q3 OPERATING INCOME EUR 3.8 MILLION VERSUS EUR 37.5
MILLION YEAR
AGO
* TRANSGENE CONFIRMS THAT IT EXPECTS TO HAVE A NET CASH BURN
TARGET OF APPROXIMATELY EUR 20 MILLION FOR 2019
* FOLLOWING RIGHTS ISSUE WHICH COMPLETED IN JULY 2019,
TRANSGENE
HAS EXTENDED ITS FINANCIAL VISIBILITY UNTIL 2022

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com;))
Gillepils liked last!
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 631
Lid geworden op: 30 mei 2018 21:25
waarderingen: 242
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Transgene And BioInvent Announce Preclinical Data For BT-001
08:21 (11/12) - Bron: Reuters
Dec 11 (Reuters) - TRANSGENE SA TRNG.PA :
* TRANSGENE AND BIOINVENT ANNOUNCE COMPELLING PRECLINICAL
DATA FOR
BT-001 IN SOLID TUMORS
* BT-001 IS A NOVEL INVIR.IO® BASED ONCOLYTIC VIRUS
EXPRESSING A
TREG-DEPLETING ANTI-CTLA4 ANTIBODY AND CYTOKINE GM-CSF
* REGULATORY SUBMISSION FOR FIRST CLINICAL TRIAL IN EUROPE
AND US
IN H1 2020
* BROAD ANTITUMOR ACTIVITY SHOWN IN IMMUNOCOMPETENT MODELS
SENSITIVE OR RESISTANT TO IMMUNE CHECKPOINT BLOCKADE
* BIOINVENT AND TRANSGENE CONFIRM THAT THEY INTEND TO SUBMIT
CLINICAL TRIAL APPLICATION IN FIRST HALF OF 2020 TO CONDUCT
FIRST-IN-HUMAN TRIAL WITH BT-001 IN EUROPE AND IN USA
* THE THERAPEUTIC ACTIVITY WAS ASSESSED IN SEVERAL
IMMUNOCOMPETENT
PRECLINICAL MODELS, SHOWING OUTSTANDING ANTITUMORAL ACTIVITY FOR
BT-001 MURINE SURROGATE ANTIBODY-ENCODING VIRUSES CONFERRING
CURES IN A MAJORITY OF MICE TRANSPLANTED WITH DIFFERENT SOLID
CANCER TUMORS (> 70% IN ALL TESTED MODELS)
* NEW PRECLINICAL DATA ALSO CONFIRMED THAT ANTI-CTLA4
ANTIBODY
EXPRESSED BY BT-001 IN MOUSE TUMOR CELLS RETAINED BIOCHEMICAL
INTEGRITY AND FOLDING, FUNCTIONALITY, AND BIOLOGICAL ACTIVITY
* BT-001’S BIODISTRIBUTION PROFILE DEMONSTRATED HIGHER
CONCENTRATION AND PROLONGED ACTIVITY OF THE ANTI-CTLA4
ANTIBODIES IN TUMORS COMPARED TO INTRAVENOUS ANTI-CTLA4 ANTIBODY
THERAPY

Source text for Eikon:
Further company coverage: TRNG.PA

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com;))
mongoose liked last!
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 631
Lid geworden op: 30 mei 2018 21:25
waarderingen: 242
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Transgene Reports On Combination Trial Of TG4010, Chemotherapy And Nivolumab
18:15 (12/12) - Bron: Reuters
Dec 12 (Reuters) - TRANSGENE SA TRNG.PA :
* TRANSGENE REPORTS ON THE COMBINATION TRIAL OF TG4010,
CHEMOTHERAPY AND NIVOLUMAB IN NON-SMALL CELL LUNG CANCER
* TRANSGENE SA - STUDY FAILS TO MEET PRIMARY ENDPOINT OF
OVERALL
RESPONSE RATE IN PATIENTS WHOSE TUMORS EXPRESS LOW-TO-NO PD-L1

* TRANSGENE SA - ADDITIONAL DATA ANALYSES ARE STILL ONGOING
AND
COMPLETE STUDY RESULTS WILL BE PRESENTED AT AN UPCOMING
SCIENTIFIC CONFERENCE.
* TRANSGENE SA - WITH FUNDING UNTIL 2022 OUR STRATEGY
REMAINS
CLEAR AND UNCHANGED
* TRANSGENE SA - PHASE 2 COMBINATION TRIAL OF TG4001 IN
HPV-POSITIVE CANCERS IS RECRUITING WELL
* TRANSGENE SA - PHASE 2 COMBINATION TRIAL OF TG4001 IN
HPV-POSITIVE CANCERS: NEXT CLINICAL READOUT PLANNED IN H1 2020
* TRANSGENE SA - CLINICAL SITES HAVE BEEN INITIATED AND
FIRST TWO
TRIALS EVALUATING TG4050 WILL SOON BE ENROLLING PATIENTS
* TRANSGENE SA - WE EXPECT TO SUBMIT A CLINICAL TRIAL
APPLICATION
IN FIRST HALF OF 2020 FOR BT-001

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Alweer een studie in de vuilbak, en een grote partner die zal verdwijnen (BMS).
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 631
Lid geworden op: 30 mei 2018 21:25
waarderingen: 242
Contacteer:

Re: Transgene

Bericht door And its gone! »

Theoretische opening 0.38€ alstublieft!
GOOGL, BAYN, DBK, CYAD, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, YMAB, BCYC, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL.

Brammeke
Forum veteraan
Forum veteraan
Berichten: 1111
Lid geworden op: 19 okt 2016 15:33
waarderingen: 437
Contacteer:

Re: Transgene

Bericht door Brammeke »

Deze heb ik gelukkig al hele tijd geleden "buitengezwierd" ;) .

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen.


Plaats reactie